German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan’s Kyowa Kirin, which are presently sold by affiliate companies crossed Europe.
The archetypal signifier of the rights transfer is the enactment of a associated task betwixt the 2 companies – 51% owned by Grünenthal – that volition person rights to the brands, which person yearly revenues of astir €200 cardinal ($207 million) a year.
In aboriginal 2026, Grünenthal intends to bargain retired the remaining involvement successful the JV to assertion afloat power of the products, which see fentanyl-based products Abstral and PecFent for breakthrough crab pain, Moventig (naloxegol) for opioid-induced constipation, and nutritional supplement Adcal-D3 for osteoporosis.
The privately-held institution is paying €80 cardinal upfront to Kyowa Kirin, which is besides successful enactment for royalties implicit the word of the collaboration and a final, undisclosed outgo erstwhile the existent narration ends. Grünenthal’s ain revenues were astir €1.5 cardinal successful 2021.
The symptom products complement the German drugmaker’s existent portfolio which includes a topical capsaicin merchandise called Qutenza for post-shingles nervus symptom and diabetic nervus symptom affecting the feet, on with non-opioid analgesic resiniferatoxin which precocious precocious into signifier 3 investigating successful patients with osteoarthritis.
“As a person successful symptom management, and with our proven way grounds successful increasing established brands, we judge we tin assistance adjacent much patients payment from this unsocial radical of medicines,” said Gabriel Baertschi, Grünenthal’s main enforcement (pictured above).
“This portfolio of established brands matches precise good with Grünenthal’s geographical footprint and therapeutic areas,” helium added.
The German institution is nary alien to increasing its portfolio by buying older brands, having invested €2 cardinal successful M&A transactions successful the past mates of years.
Jut a fewer weeks agone it closed the acquisition of testosterone replacement therapy Nebido for antheral hypogonadism from Bayer successful European and Latin American markets, successful instrumentality for a outgo of €495 million.
Earlier deals included taking rights to cholesterin cause Crestor, gastrointestinal illness therapy Nexium (esomeprazole), migraine therapy Zomig (zolmitriptan), and anti-inflammatory cause Vimovo (naproxen/esomeprazole) from AstraZeneca, arsenic good arsenic ownership of Qutenza from Acorda Therapeutics.
And past year, its acquisition of Swiss biotech institution Mestex for an undisclosed sum added resiniferatoxin to its pipeline.
English (US)